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To assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and
modified Rankin Scale (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized
anti-CD19 monoclonal antibody, in participants with neuromyelitis optica spectrum disorder
(NMOSD).
Methods
Adults (N = 230) with aquaporin-4 immunoglobulin G-seropositive NMOSD or -seronegative
neuromyelitis optica and an EDSS score ≤8 were randomized (3:1) to receive inebilizumab
300mg or placebo on days 1 and 15. The randomized controlled period (RCP) was 28 weeks or
until adjudicated attack, with an option to enter the inebilizumab open-label period. Three-
month EDSS-confirmed disability progression (CDP) was assessed using a Cox proportional
hazard model. The effect of baseline subgroups on disability was assessed by interaction tests.
mRS scores from the RCP were analyzed by the Wilcoxon-Mann-Whitney odds approach.
Results
Compared with placebo, inebilizumab reduced the risk of 3-month CDP (hazard ratio [HR]:
0.375; 95% CI: 0.148–0.952; p = 0.0390). Baseline disability, prestudy attack frequency, and
disease duration did not affect the treatment effect observed with inebilizumab (HRs:
0.213–0.503; interaction tests: all p > 0.05, indicating no effect of baseline covariates on
outcome). Mean EDSS scores improved with longer-term treatment. Inebilizumab-treated
participants were more likely to have a favorable mRS outcome at the end of the RCP (OR:
1.663; 95% CI: 1.195–2.385; p = 0.0023).
Conclusions
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Classification of Evidence
This study provides Class II evidence that for patients with NMOSD, inebilizumab reduces the risk of worsening disability.
N-MOmentum is registered at ClinicalTrials.gov: NCT02200770.
Neuromyelitis optica spectrum disorder (NMOSD) is a rare,
chronic, autoimmune disorder of the CNS, characterized by a
relapsing course of severe attacks of optic neuritis and transverse
myelitis; brain, diencephalic, and brainstem lesions occur less
commonly.1–4 Accrual of severe disability in NMOSD appears to
be driven primarily by irreversible attack-related injury, although
emerging evidence suggests that subclinical disease processes may
be present.5–8
Immunosuppression is typically used in NMOSD to reduce the
risk of attacks. There are limited data on the effect of drugs used
empirically in NMOSD on disability.9,10 Eculizumab11 and satra-
lizumab12 significantly reduced the risk of NMOSD attack, but
significant effects on disability-related outcomes were not reported.
B cells have an important role in NMOSD pathogenesis.13,14
Inebilizumab, a B-cell-depleting antibody targeting CD19, was
evaluated in a randomized, double-blind, placebo-controlled
study (N-MOmentum).15 Inebilizumab significantly reduced
the risk of NMOSD attack and worsening disability, and was
associated with fewer new MRI lesions and disease-related
hospitalizations. The most common adverse reactions (≥10%
of participants treated with inebilizumab and greater than
placebo) were urinary tract infection and arthralgia.
Standard measures of Expanded Disability Status Scale (EDSS)
score changes, typically used in studies of MS, use continuous
measurement of EDSS with annualized relapse rate as a measure
of effect. Such measurements are not possible in the time to
event design used in this study, whichwas required for the ethical
use of a placebo control.16 Although the initial N-MOmentum
study results reported reduced frequency of worsening disability
in inebilizumab-treated participants compared with the placebo
group,15 this article presents detailed, preplanned, and post hoc
analyses of disability outcomes, with specific consideration to
assessing disability in NMOSD clinical trials.
Methods
Study Design and Participants
The N-MOmentum study was an international, randomized,
double-blind, placebo-controlled, phase 2/3 trial with an
optional open-label extension phase. The study design (in-
cluding CONSORT flow diagram) was described previously.15
In brief, adults (aged ≥18 years) with a diagnosis of
NMOSD who had an EDSS score ≤8.0 and a history of
either at least 1 attack in the previous year or at least 2
attacks in the previous 2 years were eligible. A single ref-
erence laboratory (Mayo Clinic, Rochester, MN) de-
termined aquaporin-4 immunoglobulin G (AQP4-IgG)
status. Both AQP4-IgG-seropositive and -seronegative pa-
tients were enrolled; AQP4-IgG-seronegative patients
needed to meet the 2006 neuromyelitis optica diagnostic
criteria,17 verified by an eligibility committee.
Following screening, eligible participants were randomized
(3:1) to IV inebilizumab 300 mg or placebo (saline) admin-
istered on days 1 and 15 of the randomized controlled period
(RCP). Use of other immunosuppressants was prohibited
during the study. Participants continued in the RCP for up to
28 weeks or until occurrence of an adjudicated attack, at which
point they had the option to transition to the open-label
extension.
Enrollment was stopped after 230 participants were ran-
domized and dosed, based on recommendation from the
Independent Data Monitoring Committee due to clear evi-
dence of inebilizumab efficacy.
Standard Protocol Approvals, Registrations,
and Patient Consents
The N-MOmentum trial is registered at ClinicalTrials.gov
(NCT02200770). The study was conducted in accordance
with the International Conference on Harmonisation Guide-
lines for Good Clinical Practice and the principles of the
Declaration of Helsinki in its currently applicable version. An
institutional review board or ethics committee at each study site
approved the protocol.Written informed consent was obtained
from all participants.
Outcome Measures
Disability was assessed using the EDSS18 and the modified
Rankin Scale (mRS).19 A qualified, independent rater using
the Neurostatus e-Scoring (NESC) system performed the
Glossary
AQP4-IgG = aquaporin-4 immunoglobulin G; CDP = confirmed disability progression; EDSS = Expanded Disability Status
Scale; HR = hazard ratio; mRS = modified Rankin Scale; NESC = Neurostatus e-Scoring; NMOSD = neuromyelitis optica
spectrum disorder; NNT = number needed to treat; OLP = open-label period; OSIS = Opticospinal Impairment Scale; PI =
principal investigator; RCP = randomized controlled period; WMWodds = Wilcoxon-Mann-Whitney odds.
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EDSS assessment. EDSS assessments were conducted within
5 days of the report of a potential attack. NESC is an elec-
tronic data capture, analysis, and management system de-
veloped at the University of Basel to improve consistency and
reduce measurement noise for the EDSS.20 An integrated
algorithm provides real-time feedback to flag potential in-
consistencies in the final EDSS score, which can then be re-
solved by the EDSS assessor. EDSS scores were assessed at
baseline, at RCP weeks 12 and 28, every 3 months in the
open-label period (OLP), and at any attack assessment visit
for new or worsening NMOSD symptoms.
The study investigator evaluated the mRS score at baseline, at
RCP weeks 4, 8, 12, 16, 22, and 28, and at any assessment visit
for new or worsening NMOSD symptoms. The mRS score
ranges from 0 (no symptoms) to 6 (dead) (appendix e-1,
links.lww.com/NXI/A454), and changes in mRS score were
assessed from baseline to the last RCP visit.
Attack severity was graded according to a modified version of
the Opticospinal Impairment Scale (OSIS),21,22 which char-
acterizes attacks as major or minor based on changes in
domain-specific scores for neurologic function. Attack re-
covery assessment was performed 28 days after the attack and
was graded according to change in the same domain-specific
scores relative to the score at the time of attack. Details of the
scale and scoring are provided in appendix e-2, links.lww.
com/NXI/A454.
Statistical Analyses
Analyses were performed for the intent-to-treat population,
defined as study participants who were randomized and re-
ceived any study medication. All analyses were prespecified
before unblinding of the data, unless specifically described as
post hoc.
The proportion of participants with disability worsening from
baseline, based on EDSS score, was compared between
treatment groups by logistic regression analysis, with treat-
ment, baseline EDSS score, and AQP4-IgG serostatus as ex-
planatory variables. Missing values were considered as
worsening. The last RCP visit was at 28 weeks for those
without an adjudicated attack or at the time of attack assess-
ment for those who did experience an adjudicated attack.
Disability worsening at any visit, whether scheduled or as part
of an attack assessment, was defined according to the increase
in the EDSS score from the participant’s baseline score (≥2
points from a baseline of 0; ≥1 point from a baseline of 1–5;
and ≥0.5 points from a baseline of ≥5.5).
Three post hoc analyses of EDSS data were performed to
address specific limitations of the study design and answer
additional questions. For the post hoc analyses, a 3-month
period was defined in each analysis variant as the time from
attack to the assessment of EDSS score. Treatment allocation
was respected in all cases. To mitigate concern that analysis of
EDSS worsening at the last RCP visit could be compromised
with EDSS values recorded in the setting of an acute attack
visit, the first post hoc analysis substituted data from OLP
month 3 as the final EDSS assessment time point. This was
done for participants who experienced an adjudicated attack
at their last RCP visit; the end of the RCP (week 28) was
retained for participants who did not experience an adjudi-
cated attack. This analysis allowed all participants to be
evaluated at a time point when they were not experiencing an
acute attack.
The second post hoc analysis evaluated the proportion of
participants with EDSS score worsening relative to baseline at
the end of the RCP (attack assessment, or week 28 for those
without an attack) and 3 months later (3-month confirmed
disability progression [CDP]). The purpose of this analysis
was to assess concern of a lack of longitudinal confirmation of
EDSS change by analyzing the proportion of participants with
3-month CDP from the end of the RCP, regardless of attack
occurrence.
The third analysis evaluated 3-month CDP at any time during
the RCP. The purpose of this analysis was to not limit the
analysis to the end of RCP assessment (which is most influ-
enced by attacks) and instead to compare 3-month CDP
stemming from any study visit during the RCP, as is tradi-
tionally performed in MS clinical trials. If the follow-up EDSS
score was missing, the participant was assumed to not have
3-month CDP. The first 2 analyses used logistic regression;
the third analysis used the Cox proportional hazard model.
The risk of EDSS score worsening at the end of the RCP was
evaluated in prespecified subgroups dichotomized by the
baseline EDSS score (<5 vs ≥5; the cutoff at 5 represents the
point where disease affects daily activities to a degree that
requires special provisions), number of prior NMOSD attacks
(<2 vs ≥2; cutoff selected based on the inclusion criteria of
attacks in the 2 years before enrollment), and disease duration
(<5 vs ≥5 years; the cutoff of 5 years was chosen to represent
those with longer-term disease), all characteristics presumed
to reflect disease severity. p Values are presented for the in-
teraction test in each case, where p > 0.05 indicates no sta-
tistically significant difference in treatment effect between
subgroups. The mean change in EDSS was plotted, with
standard error, for the RCP and to month 12 of the OLP.
The last postbaseline mRS scores in the RCP were analyzed
using the Wilcoxon-Mann-Whitney odds (WMWodds) ap-
proach, where all possible pairs of the between-group differ-
ence in mRS outcomes are compared.23,24 This prespecified
analysis approach was selected because it requires no as-
sumptions about the distribution of the ordinal outcome data,
and it enables a measure of the effect size with CIs. The
distribution of mRS scores at baseline and end of the RCP for
each treatment group are presented descriptively. The pro-
portion of participants with major or minor attacks was
compared between treatment arms using the Fisher exact test.
All statistical analyses were performed using SAS version 9.4.
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Classification of Evidence
This study provides Class II evidence that, relative to pla-
cebo, participants with NMOSD receiving inebilizumab had
a lower risk of 3-month CDP from any point in the RCP
(hazard ratio [HR]: 0.375; 95% CI: 0.148–0.952; p = 0.0390).
Inebilizumab-treated participants experienced a lower risk of
EDSS worsening relative to those receiving placebo, with no
differences in treatment effect size (OR; 95% CI; interaction
test p value) seen among subgroups dichotomized accord-
ing to baseline EDSS score (EDSS <5: 0.375 [0.155–0.906];
EDSS ≥5: 0.360 [0.109–1.191]; p = 0.8908), attack his-
tory (<2 attacks: 0.503 [0.082–3.081]; ≥2 attacks: 0.322
[0.150–0.692]; p = 0.6215), or disease duration (<5 years:
0.417 [0.193–0.899]; ≥5 years: 0.213 [0.038–1.187]; p= 0.5342),
and were more likely to report lower mRS disability scores at
the end of the RCP (WMWodds: 1.663; 95% CI: 1.195–2.385;
p = 0.0023).
Data Availability
Anonymized/deidentified data sets for defined study out-
comes will be made available on reasonable request. Proposals
should be directed to katze@vielabio.com. Requestors will be
required to sign a data access agreement. Requests will be
considered up to 3 years following article publication.
Results
Study Participants
A total of 230 participants received study medication (inebi-
lizumab: n = 174; placebo: n = 56). Baseline demographics
and characteristics were generally similar between treatment
groups (table). Most participants were women (n = 209;
90.9%). The mean (SD) age was 42.9 (12.2) years. The mean
(SD) disease duration was 2.4 (3.3) years in the inebilizumab







Age, years, mean (SD) 42.6
(13.9)
43.0 (11.6)
Sex, women 50 (89.3) 159 (91.4)
Race
American Indian/Alaskan Native 5 (8.9) 14 (8.0)
Asian 8 (14.3) 39 (22.4)
Black or African American 5 (8.9) 15 (8.6)
White 28 (50.0) 92 (52.9)
Other/multiple categories checked 10 (17.9) 14 (8.0)
Disease duration, years, mean (SD) 2.8 (3.5) 2.4 (3.3)
Disease duration
<5 years 46 (82.1) 144 (82.8)
≥5 years 10 (17.9) 30 (17.2)
Most recent attack
Optic neuritis 21 (37.5) 85 (48.9)
Myelitis 34 (60.7) 99 (56.9)
Brain/brainstem 10 (17.9) 8 (4.6)
Number of Gd+ lesions at baseline,
mean (SD)
0.9 (0.9) 1.2 (1.2)




0 0 (0.0) 4 (2.3)
1–4.5 40 (71.4) 129 (74.1)
≥5 16 (28.6) 41 (23.6)
mRS score, median (range) 2 (0–5) 2 (0–5)
mRS category
0 2 (3.6) 26 (14.9)
1 21 (37.5) 55 (31.6)
2 17 (30.4) 49 (28.2)
3 5 (8.9) 16 (9.2)
4 9 (16.1) 26 (14.9)
5 2 (3.6) 2 (1.1)
Modified Opticospinal Impairment
Scale, median (range)
Visual acuity 1.5 (1–7) 1 (1–6)
Motor function 2 (0–7) 1 (0–7)
Brain function 0 (0–2) 0 (0–4)
Brainstem function 0 (0–4) 0 (0–4)
Table Summary of Baseline Demographics and







category (with score ≥3), %
Visual acuity 26.8 16.1
Motor function 28.6 27.6
Brain function 0 0.6
Brainstem function 5.4 3.4
Number of prior attacks
<2 14 (25.0) 25 (14.4)
≥2 42 (75.0) 149 (85.6)
Abbreviations: EDSS = Expanded Disability Status Scale; Gd+ = gadolinium-
enhancing; mRS = modified Rankin Scale.
Data are n (%), unless otherwise stated.
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group and 2.8 (3.5) years in the placebo group. The median
(range) EDSS score at baseline was 3.5 (0–8.0) for partici-
pants receiving inebilizumab and 4.0 (1.0–8.0) for those re-
ceiving placebo. The proportion of participants with an EDSS
score of 5 or above at baseline was 23.6% in the inebilizumab
group and 28.6% in the placebo group. The median (range)
mRS score at baseline was 2 (0–5) in both treatment groups.
EDSS Outcomes
The proportion of participants who had protocol-defined
EDSS worsening at the end of the RCP (at 28 weeks/
occurrence of adjudicated attack) was lower with inebilizu-
mab treatment (15.5% [27/174]) than with placebo (33.9%
[19/56]; OR: 0.370; 95% CI: 0.185–0.739; p = 0.0049).15
The number needed to treat (NNT) with inebilizumab to
prevent 1 case of EDSS score worsening at 28 weeks was 6.
The trial design for N-MOmentum implemented an event-
based study design: for those participants who experienced an
attack, this likely means that the EDSS score for these
participants was measured at its likely maximum value, com-
pared with the baseline level of disability experienced by
participants.
Reduced risk of EDSS worsening with inebilizumab was,
however, confirmed in 3 post hoc analyses. In the first analysis
(designed tomitigate the confounding effect of analyzing EDSS
scores during acute attacks by substituting a post attack, con-
valescent EDSS score for those with attacks), the risk of EDSS
worsening was lower in the inebilizumab arm relative to the
placebo arm (OR: 0.284; 95% CI: 0.129–0.625; p = 0.0018)
(figure 1A).
The 2 other post hoc analyses were performed to evaluate
3-month CDP. The proportion of participants with 3-month
CDP at the end of the RCP was lower in the inebilizumab
arm (OR: 0.220; 95% CI: 0.069–0.701; p = 0.0105) (figure
1B). Importantly, results were similar when 3-month CDP
was defined as EDSS worsening from any time during the
RCP and confirmed at least 3 months later: the proportion of
Figure 1 Post Hoc Analyses of EDSS Outcomes
(A) EDSS worsening at the end of the RCP using nonattack visit data. Analysis conducted by using EDSS values from OLP month 3 for those participants who
hadAC-determined attack at their end of RCP visit (placebo: n = 15; inebilizumab: n = 14). End of theRCP visit datawere used for thosewhodidnot have attacks
(placebo: n = 0; inebilizumab: n = 2). (B) Three-month CDP from the end of the RCP visit. Analysis conducted for the subgroup of patients with EDSS worsening
at the last RCP visit irrespective of whether participants had attacks, confirmed at OLP month 3 (placebo: 7/7 had attacks; inebilizumab: 2/6 had attacks). (C)
Kaplan-Meier plot of the risk of 3-month CDP from any point in the RCP. None of those randomized to placebo with EDSSworsening at the last RCP visit had a
subsequent attack in the first 3 months of OLP. Only 1 participant randomized to inebilizumab with EDSS worsening at the last RCP visit had a subsequent
attack within the 3-month OLP window. AC = adjudication committee; CDP = confirmed disability progression; EDSS = Expanded Disability Status Scale;
HR = hazard ratio; OLP = open-label period; RCP = randomized controlled period.
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participants with 3-month CDP during the RCP was 14.3%
with placebo and 5.7% with inebilizumab (62.5% risk re-
duction; HR: 0.375; 95% CI: 0.148–0.952; p = 0.0390)
(figure 1C).
Of 27 participants receiving inebilizumab who had worsening
in EDSS score at the end of the RCP, 51.9% (14/27) had
adjudicated attacks, 3.7% (1/27) had principal investigator
(PI)-determined, nonadjudicated attack, and 44.4% (12/27)
had no attack. Of 19 placebo-treated participants who had
EDSS score worsening, 78.9% (15/19) had adjudicated at-
tacks, 5.3% (1/19) had PI-determined, nonadjudicated attack,
and 15.8% (3/19) had no attack. A similar proportion of
participants in each arm had EDSS score worsening at the end
of the RCP in the absence of any attack (inebilizumab: 6.9%
[12/174]; placebo: 5.4% [3/56]).
The prespecified subgroup analyses of EDSS score worsening
showed a consistently reduced risk in inebilizumab-treated
participants compared with placebo, regardless of the baseline
EDSS score, number of previous attacks, or disease duration,
with no significant differences in treatment effect seen with
inebilizumab observed among these subgroups (figure 2).
In the first year of the OLP, when all participants received
inebilizumab, the mean change in EDSS scores decreased in
participants originally treated with inebilizumab and in those
originally treated with placebo (figure 3A). The curves for
mean change in EDSS were approximately parallel during the
OLP in the 2 treatment arms and did not converge (figure
3A). Mean changes in EDSS scores for the subgroups with
and without attacks during the RCP are shown in figure 3, B
and C.
mRS Outcomes
The prespecified analysis showed that mRS outcomes at the
end of the RCP were better with inebilizumab than with
placebo treatment in 51.5% of cases, equal in 21.9% of cases,
and worse in 26.6% of cases. Participants treated with inebi-
lizumab were 66.3% more likely to report less disability at the
end of the RCP compared with placebo treatment (OR:
1.663; 95% CI: 1.195–2.385; p = 0.0023) (figure 4A). Similar
proportions of participants had no symptoms or no significant
disability (mRS score <2) at baseline in the inebilizumab
(46.6%) and placebo (41.1%) groups. By the end of the RCP,
the proportion of participants without significant disability
remained stable with inebilizumab (48.3%), but fell with
placebo (33.9%) (figure 4B, C).
Attack Incidence, Severity, Recovery, and Use
of Rescue Medication
None of those randomized to placebo with EDSS worsening
at the last RCP visit had a subsequent attack in the first 3
months of OLP. Only 1 participant randomized to inebili-
zumab with EDSS worsening at the last RCP visit had a
subsequent attack within the 3-month OLP window.
Attack severity, measured by the modified OSIS scale,21,22
numerically favored inebilizumab treatment, with attack se-
verity graded as major in 29% of inebilizumab attacks vs 45%
of placebo attacks (p = 0.35; figure e-1A, links.lww.com/NXI/
A454). The degree of recovery from attacks was nominally
Figure 2 Subgroup Analyses of EDSS Outcomes
Figure shows the risk of EDSS score worsening from baseline to the end of the RCP. EDSS = Expanded Disability Status Scale; HR = hazard ratio; RCP =
randomized controlled period.
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better with inebilizumab (figure e-1B), although this analysis
is confounded by differences in attack severity.
Rescue therapy was allowed according to the N-MOmentum
study protocol and was administered at the discretion of the
study investigator. Steroid therapy was used in the vast majority
of attacks, with only 1 participant (randomized to inebilizu-
mab) who did not receive steroid treatment. Most received IV
steroid treatment (34 participants received 1,000 mg doses; 3
received 500mg doses), with 1 participant receiving a 1,000mg
dose of oral steroids. Conversely, plasmapheresis was used to
treat a minority of attacks and was administered to a similar
Figure 3 Post Hoc Analysis of Change in Mean EDSS Scores During the RCP and OLP
(A)Overall population. (B) Participantswith attacks in the RCP. (C) Participantswithout attacks in the RCP. EDSS = ExpandedDisability Status Scale; OLP = open-
label period; RCP = randomized controlled period.
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number of participants in each treatment group (6/22 attacks
in the placebo group [27.3%]; 5/21 in the inebilizumab group
[23.8%]). As such, the rescue therapies used in the treatment of
acute attacks were similar in both the placebo and inebilizumab
groups and are unlikely to have influenced the observed dif-
ferences in disability outcomes.
Discussion
NMOSD is associated with substantial morbidity and mor-
tality. A review of over 100 patients with NMOSD reported
that 18% developed permanent visual disability, 34% de-
veloped permanent motor disability, and 23% became
wheelchair dependent at a median follow-up of 75 months
after disease onset.25 A retrospective analysis of 175 patients
with NMOSD showed that disability accrued over time, with
a median annualized increase in the EDSS score of 0.65 in
patients with a disease duration of ≥12 months.26 The me-
dian EDSS score was 5 at 58 months (median) after disease
onset, indicating impaired ambulation; the median disease
duration until patients required a walking aid (EDSS score of
6 or 6.5) was 94 months.26 Mortality in the 2 studies was 9%
and 6% of patients at a median follow-up of 99 and 116
months, respectively.25,26
Several factors influence clinical outcomes in patients with
NMOSD. Ethnicity, onset age, and onset attack type appear to
affect disease outcomes.25,27–29 Higher attack frequency predicts
severe motor disabilities,28 as does delay in diagnosis/preventive
treatment.29 Here, we found that the impact of inebilizumab
treatment was not influenced by baseline participant character-
istics (figure 2).
The current approved treatment options for patients with
NMOSD are limited. Inebilizumab is approved in the United
States for treatment of AQP4-IgG-seropositive adults with
NMOSD.30 The results described here confirm that
inebilizumab reduces the risk of disability worsening in
Figure 4 mRS Outcomes During the RCP
(A) Treatment effect basedon themRS score during the RCP. (B) Distribution ofmRS scores at baseline and at the last RCP visit in patients treatedwith placebo.
(C) Distribution of mRS scores at baseline and at the last RCP visit in patients treated with inebilizumab. mRS = modified Rankin Scale; RCP = randomized
controlled period; WMWodds = Wilcoxon-Mann-Whitney odds.
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individuals with NMOSD. The treatment effect is sustained
across multiple subgroups, supporting a benefit of inebilizumab
in a broad spectrum of patients with NMOSD. TheNNT shows
that only 6 inebilizumab-treated patients are needed to prevent 1
case of worsening disability after 6.5months. Beneficial effects on
disability measures were previously reported with azathioprine31
and rituximab,9,32 although evidence is limited to uncontrolled,
observational studies. Rituximab provided larger reductions in
the EDSS score from baseline when compared with azathioprine
in a randomized, open-label study of NMOSD,33 but showed no
difference to placebo in a double-blind study.34
Eculizumab, a terminal complement inhibitor, is also approved
for the treatment of adults with AQP4-IgG-seropositive
NMOSD.35,36 Eculizumab significantly reduced the risk of
attack in a randomized, double-blind, placebo-controlled trial in
AQP4-IgG-seropositive participants with NMOSD.11
However, no significant difference was observed between the
groups for disability progression.11 Satralizumab, a humanized,
anti–interleukin-6 receptor monoclonal antibody, also dem-
onstrated reduction in attacks but no significant effects on
disability.12 There is a possibility that the absence of significant
impact of these 2 drugs on disability may be due to differences
inmechanism of action, but differences in study design and lack
of statistical power are more likely explanations.
As recently reviewed by Levy et al.,37 attack rates cannot be
compared directly between studies owing to the contrasting study
designs. Differences in the use of attack criteria, attack adjudica-
tion, the censoring of attack events, and differing prior and on-
study concomitant therapy all combine to confound interstudy
interpretation. The difference in study designs may also be a
factor with regard to disability outcomes. The increased power
afforded by the number of patients enrolled inN-MOmentum, as
well as the mechanism used to control for multiplicity testing in
the key secondary end points, may have made N-MOmentum
more sensitive to differences in disability outcomes. It should also
be considered that the EDSS is known to be dominated by
ambulation18 and may be less sensitive to disability induced by
changes in visual or cognitive function. Use of a broader range of
metrics, such as the mRS, may be useful to detect effects on
disability in future studies of NMOSD.
Methods for analyzing disability in NMOSD were adapted from
MS trials. Pivotal MS trials typically measure EDSS scores over 2
or more years, and 3-month CDP is commonly reported. Ap-
plying these techniques to NMOSD studies is challenging due to
differences in study design. To reduce risks related to placebo
exposure, the N-MOmentum study offered inebilizumab to par-
ticipants following adjudicated attacks. As a consequence, analysis
of 3-month CDP is confounded by inebilizumab treatment.
This article presents additional analyses to address the limi-
tations of the study design and the confounding influence of
inebilizumab treatment. The post hoc analyses presented in
the article validate the outcomes despite the limitations of trial
design used in the N-MOmentum study. The predefined
analysis of disability worsening as the secondary end point of
the study, combined with the 3 post hoc analyses done to
provide a 3-month CDP, establishes a clear benefit of inebi-
lizumab treatment on disability worsening. Moreover, the bias
on 3-month CDP introduced by inebilizumab treatment fol-
lowing attacks, or at the end of the RCP, would actually re-
duce the estimate of the impact of inebilizumab on disability
and therefore is unlikely to affect the validity of the CDP
analyses. In addition, the ORs calculated as part of the original
study analysis15 compared favorably with those calculated as
part of the post hoc analyses (0.370 vs 0.220–0.375, re-
spectively) and provide further confidence in these findings.
The benefit of inebilizumab on disability outcomes was
underscored by data collected during the OLP. With 12
months of open-label treatment, net improvement in the EDSS
score was observed in both treatment groups. Participants
randomized to inebilizumab had lower EDSS scores compared
with baseline. Participants initially receiving placebo experi-
enced EDSS score worsening by the end of the RCP, but EDSS
scores improved following 1 year of inebilizumab treatment
(figure 3A). Improvement in disability may therefore occur in
some participants treated with inebilizumab. Another impor-
tant observation is that by OLP month 12, disability scores in
participants randomized to placebo remained higher than those
randomized to inebilizumab, suggesting that even a 6-month
delay in initiation of treatment may persistently affect disability.
The mRS analysis supports the conclusion that inebilizumab
treatment reduces the risk of disability worsening in NMOSD
(figure 4). The fact that inebilizumab had an impact on the
mRS is particularly noteworthy as the mRS strictly measures
gross disability, as opposed to neurologic impairments that
may contribute to disability and which are measured by the
lower ranges of the EDSS scale.
Inebilizumab might also lessen NMOSD attack severity (fig-
ure e-1, links.lww.com/NXI/A454) through a reduction in
inflammatory damage during attacks. This hypothesis is
consistent with the observation that serum glial fibrillary
acidic protein, a marker of astrocyte damage, increased to a
lesser extent during NMOSD attacks in inebilizumab-treated
participants compared with placebo-treated individuals.38
Although EDSS score worsening was associated with an ad-
judicated attack in most cases, some participants experienced
EDSS score worsening without an attack. There are several
possible causes of EDSS score worsening in the absence of an
adjudicated attack, including occurrence of a nonadjudicated
attack, fluctuation in signs and symptoms, measurement
variability, and attack-independent CNS injury. In 2/17
(11.8%) cases of EDSS score worsening, the participants ex-
perienced an attack that did not meet adjudication criteria,
and both were MRI negative. A similar proportion of partic-
ipants in the 2 treatment arms had EDSS score worsening at
the end of the RCP in the absence of attacks (inebilizumab:
6.9%; placebo: 5.4%). This may represent the approximate
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rate of events that are attributable to fluctuation in symptoms
or measurement variability. Another possible explanation for
EDSS score worsening in the absence of attacks is the accu-
mulation of subclinical injury. Subclinical demyelination,5
cervical spinal cord atrophy,6 retinal pathology,7,39,40 and
changes in visual evoked potential findings have been repor-
ted in NMOSD.41
The study had several limitations. First, the design limited
evaluation of long-term disability outcomes by treatment arm.
Second, the EDSS was developed and validated for use in MS
and, despite clinical overlap, the EDSS was not previously vali-
dated inNMOSD. Furthermore, at higher ranges of the scale, the
EDSS is primarily a measure of walking ability. Consequently, it
likely has low sensitivity for detecting neurologic worsening
unrelated to ambulation (e.g., optic nerve or brainstem injury)
and hence could underestimate the rate of important disability
worsening in nonambulatory participants. In addition, standard
measures of EDSS score changes such as those used in studies of
MS are not possible in the time to event design used in this study,
which was required for the ethical use of a placebo control.15,16
With 3 treatments now approved for NMOSD, study designs
including a placebo arm will no longer be required. Future study
designs can therefore be longer, with EDSS and other disability
scores measured in a more controlled manner.
In conclusion, these analyses demonstrated that compared
with placebo, inebilizumab improves disability outcomes in
individuals with NMOSD. Inebilizumab showed a consistent
effect in reducing the risk of disability worsening compared
with placebo, as measured by the EDSS or mRS score, re-
gardless of baseline disability status, attack history, or disease
duration, underlining the positive effect of inebilizumab on
disability in participants with NMOSD.
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